195 related articles for article (PubMed ID: 34381173)
41. OPRM1 genotype and naltrexone response in depressed alcohol-dependent patients.
Foulds JA; Ton K; Kennedy MA; Adamson SJ; Mulder RT; Sellman JD
Pharmacogenet Genomics; 2015 May; 25(5):270-3. PubMed ID: 25715171
[TBL] [Abstract][Full Text] [Related]
42. Real-time assessment of alcohol craving and naltrexone treatment responsiveness in a randomized clinical trial.
Miranda R; Treloar Padovano H; Gray JC; Wemm SE; Blanchard A
Addict Behav; 2018 Aug; 83():72-78. PubMed ID: 29395188
[TBL] [Abstract][Full Text] [Related]
43. The Kappa Opioid Receptor Is Associated With Naltrexone-Induced Reduction of Drinking and Craving.
de Laat B; Goldberg A; Shi J; Tetrault JM; Nabulsi N; Zheng MQ; Najafzadeh S; Gao H; Kapinos M; Ropchan J; O'Malley SS; Huang Y; Morris ED; Krishnan-Sarin S
Biol Psychiatry; 2019 Dec; 86(11):864-871. PubMed ID: 31399255
[TBL] [Abstract][Full Text] [Related]
44. Neuroimaging findings from an experimental pharmacology trial of naltrexone in heavy drinkers of East Asian descent.
Lim AC; Ghahremani DG; Grodin EN; Green R; Bujarski S; Hartwell EE; Courtney KE; Hutchison K; Miotto K; Ray LA
Drug Alcohol Depend; 2019 Jul; 200():181-190. PubMed ID: 31160146
[TBL] [Abstract][Full Text] [Related]
45. OPRM1 Moderates Daily Associations of Naltrexone Adherence With Alcohol Consumption: Preliminary Evidence From a Mobile Health Trial.
Hendershot CS; Dermody SS; Wardell JD; Zaso MJ; Kennedy JL; Stoner SA
Alcohol Clin Exp Res; 2020 Apr; 44(4):983-991. PubMed ID: 32020635
[TBL] [Abstract][Full Text] [Related]
46. Understanding naltrexone mechanism of action and pharmacogenetics in Asian Americans via behavioral economics: a preliminary study.
Bujarski S; MacKillop J; Ray LA
Exp Clin Psychopharmacol; 2012 Jun; 20(3):181-90. PubMed ID: 22429255
[TBL] [Abstract][Full Text] [Related]
47. Predicting the effect of naltrexone and acamprosate in alcohol-dependent patients using genetic indicators.
Ooteman W; Naassila M; Koeter MW; Verheul R; Schippers GM; Houchi H; Daoust M; van den Brink W
Addict Biol; 2009 Jul; 14(3):328-37. PubMed ID: 19523047
[TBL] [Abstract][Full Text] [Related]
48. Naltrexone for the treatment of alcoholism: clinical findings, mechanisms of action, and pharmacogenetics.
Ray LA; Chin PF; Miotto K
CNS Neurol Disord Drug Targets; 2010 Mar; 9(1):13-22. PubMed ID: 20201811
[TBL] [Abstract][Full Text] [Related]
49. Pharmacogenetics of alcoholism: a clinical neuroscience perspective.
Ray LA; Courtney KE; Bujarski S; Squeglia LM
Pharmacogenomics; 2012 Jan; 13(2):129-32. PubMed ID: 22256863
[No Abstract] [Full Text] [Related]
50. Questionable efficacy for naltrexone in patients with Asp40.
Mattes JA
Arch Gen Psychiatry; 2009 Jul; 66(7):796; author reply 796-7. PubMed ID: 19581571
[No Abstract] [Full Text] [Related]
51. Genes harbor clues to addiction, recovery.
Hampton T
JAMA; 2004 Jul; 292(3):321-2. PubMed ID: 15265836
[No Abstract] [Full Text] [Related]
52. Effect of extended-release naltrexone on alcohol consumption: a systematic review and meta-analysis.
Murphy CE; Wang RC; Montoy JC; Whittaker E; Raven M
Addiction; 2022 Feb; 117(2):271-281. PubMed ID: 34033183
[TBL] [Abstract][Full Text] [Related]
53. Opioid antagonists in the treatment of alcohol dependence: clinical efficacy and prevention of relapse.
O'Malley SS
Alcohol Alcohol Suppl; 1996 Mar; 31(1):77-81. PubMed ID: 9845042
[TBL] [Abstract][Full Text] [Related]
54. [Pharmacological effects of a mu-opioid receptor antagonist naltrexone on alcohol dependence].
Kato H
Nihon Arukoru Yakubutsu Igakkai Zasshi; 2008 Oct; 43(5):697-704. PubMed ID: 19068776
[TBL] [Abstract][Full Text] [Related]
55. A multicentre, randomized, double-blind, placebo-controlled trial of naltrexone in the treatment of alcohol dependence or abuse.
Chick J; Anton R; Checinski K; Croop R; Drummond DC; Farmer R; Labriola D; Marshall J; Moncrieff J; Morgan MY; Peters T; Ritson B
Alcohol Alcohol; 2000; 35(6):587-93. PubMed ID: 11093966
[TBL] [Abstract][Full Text] [Related]
56. Extended-release vs. oral naltrexone for alcohol dependence treatment in primary care (XON).
Malone M; McDonald R; Vittitow A; Chen J; Obi R; Schatz D; Tofighi B; Garment A; Kermack A; Goldfeld K; Gold H; Laska E; Rotrosen J; Lee JD
Contemp Clin Trials; 2019 Jun; 81():102-109. PubMed ID: 30986535
[TBL] [Abstract][Full Text] [Related]
57. Opioid antagonists for alcohol dependence.
Rösner S; Hackl-Herrwerth A; Leucht S; Vecchi S; Srisurapanont M; Soyka M
Cochrane Database Syst Rev; 2010 Dec; (12):CD001867. PubMed ID: 21154349
[TBL] [Abstract][Full Text] [Related]
58. A randomized, double-blind, placebo-controlled pilot study of naltrexone in outpatients with bipolar disorder and alcohol dependence.
Brown ES; Carmody TJ; Schmitz JM; Caetano R; Adinoff B; Swann AC; John Rush A
Alcohol Clin Exp Res; 2009 Nov; 33(11):1863-9. PubMed ID: 19673746
[TBL] [Abstract][Full Text] [Related]
59. Association of the Sweet-Liking Phenotype and Craving for Alcohol With the Response to Naltrexone Treatment in Alcohol Dependence: A Randomized Clinical Trial.
Garbutt JC; Kampov-Polevoy AB; Kalka-Juhl LS; Gallop RJ
JAMA Psychiatry; 2016 Oct; 73(10):1056-1063. PubMed ID: 27627782
[TBL] [Abstract][Full Text] [Related]
60. Independent and Interactive Effects of OPRM1 and DAT1 Polymorphisms on Alcohol Consumption and Subjective Responses in Social Drinkers.
Weerts EM; Wand GS; Maher B; Xu X; Stephens MA; Yang X; McCaul ME
Alcohol Clin Exp Res; 2017 Jun; 41(6):1093-1104. PubMed ID: 28376280
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
